Albany Med is among the first hospitals in the country to obtain Food and Drug Administration (FDA) approval to use convalescent blood plasma therapy to experimentally treat critically ill patients who are infected by the novel coronavirus (COVID-19).
Convalescent plasma therapy—or plasma from a survivor of an infectious disease— was the same treatment used during the 1918 flu pandemic.
When fighting illness, the body produces antibodies—proteins that counteract a pathogen. Antibodies remain in plasma for weeks or months after recovery. The antibodies in patients who have recovered from COVID-19 attack the virus and can potentially be useful as a treatment for the virus, Albany Med officials said.